YPSOMED HLDG/  CH0019396990  /

The Ypsomed Holding AG is one of the worldwide leading independent developers and manufacturers of injection systems for self-medication and a diabetes specialist. The company offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility and other therapeutic areas. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brands mylife™ Diabetescare directly to patients or via pharmacies and hospitals as well as under YDS Ypsomed Delivery Systems in business-tobusiness operations with pharmaceutical companies.The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements; contract development and manufacturing; as well as the assembly of injection systems with medications, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide. Founded in 2003 from the wellknown company Disetronic, Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors.